The UK is launching its first Phase 3 trial of an investigational mRNA vaccine for norovirus, aimed at reducing the strain on the NHS during winter months.

This groundbreaking trial will involve approximately 25,000 adults, primarily those over 60, across more than six countries over the next two years.

Conducted in collaboration with the UK Government, NIHR, and Moderna, the trial will take place at 27 NHS hospitals and centers in England, Scotland, and Wales.

Participants will be randomly assigned to receive either the vaccine or a placebo, with close monitoring over a 25-month period.

Experts believe that a successful vaccine could significantly improve conditions in care homes and protect vulnerable individuals from severe illness.

Norovirus causes around 4 million infections annually in the UK, leading to approximately 12,000 hospital admissions and 80 deaths, highlighting the urgent need for a vaccine.

Currently, there are no approved vaccines for norovirus, and treatment for severe cases typically involves intravenous fluids.

Dr. Melanie Ivarsson, Moderna’s Chief Development Officer, expressed excitement about the trial's potential to advance mRNA technology in preventing norovirus infections.

Streeting emphasized that a successful vaccine could significantly reduce the annual cost of norovirus outbreaks to the NHS, which exceeds £100 million.

Health and Social Care Secretary Wes Streeting praised the trial as a significant boost for the UK’s life sciences sector and a step towards a preventative healthcare system.

If the vaccine proves at least 65% effective, further trials may expand its use to protect children, although this could take several years.

This trial is part of a 10-year partnership between Moderna and the UK Government, which also includes the establishment of a new mRNA manufacturing facility.